To explore the potential role of the parasympathetic nervous system in human glucoregulatory physiology, responses to the muscarinic cholinergic agonist bethanechol (5.0 mg s.c.) and antagonist atropine (1.0 mg i.v.) were measured in normal humans. There were no changes in the plasma glucose concentration or rates of glucose production or utilization following atropine administration. After bethanechol administration there were no changes in the plasma glucose concentration or fluxes despite increments in plasma glucagon (75±7 to 103±10 pg/mi, P < 0.02). There were no changes in insulin or C-peptide levels. To test the hypothesis that direct muscarinic inhibition of glucose production was offset by an indirect action of the agonist, specifically increased glucagon secretion with consequent stimulation of glucose production, bethanechol was administered while glucagon levels were held constant with the islet clamp technique (somatostatin infusion with insulin, glucagon and growth hormone replacement at fixed rates). Under that condition the muscarinic agonist induced a 25% decrement in the plasma glucose concentration (101±8 to 75±8 mg/dl, P < 0.05). When compared with separate clamp control studies (with placebo rather than bethanechol injection) both the rate of glucose production and the glucose concentration were reduced (P < 0.05) following bethanechol injection; the rate of glucose utilization was unaltered. Thus, we conclude: Withdrawal of parasympathetic tone does not appear to be an important glucoregulatory process in humans. Direct muscarinic cholinergic inhibition of hepatic glucose production occurs in humans but during generalized muscarinic activation this is offset by an indirect muscarinic action, increased glucagon secretion with consequent stimulation of glucose production. Thus, particularly if regional neuronal firing occurs, the parasympathetic nervous system may play an important role in human glucoregulatory physiology. dose of 20 ,Ci of 3-[3H]glucose (1 1.5 Ci/mmol, New England Nuclear, Boston, MA) was administered intravenously; a dose 0.2 pCi/min was Muscarinic Inhibition ofGlucose Production 445 J. Clin. Invest.
Introduction
The potential role of the parasympathetic nervous system in human glucoregulatory physiology and pathophysiology has not been explored in depth. This contrasts with the role of the sympathochromaffin system, including the sympathetic nervous system, which has been studied rather extensively (1) . In animals both the liver (2, 3) and the pancreatic islets (4) (5) (6) receive cholinergic, as well as adrenergic and peptidergic, innervation, and stimulation ofparasympathetic nerves has been reported to reduce hepatic glucose output (2, 3, 7) . Further, administration ofthe muscarinic antagonist atropine appeared to increase hepatic glucose release in dogs (8) . However, neither the acetylcholinesterase inhibitor edrophonium (9, 10) nor the muscarinic agonist bethanechol (9) have been found to alter the plasma glucose concentration in humans.
The concept of direct and indirect (hormone mediated) metabolic actions of a given glucoregulatory factor, which emerged from studies of the mechanisms of the hyperglycemic effect of the catecholamines (1) , may also be relevant to the study of potential glucoregulatory effects of the parasympathetic nervous system. For example, the hyperglycemic response to epinephrine is the result of both its direct action to stimulate hepatic glucose production and limit glucose utilization and the indirect action of the hormone to restrain insulin secretion (1, 1 1). Indeed, modulation of insulin secretion is a critical glucoregulatory event in that restraint of insulin secretion by epinephrine permits the hyperglycemic response to the hormone to occur, but a small increase in insulin secretion limits the magnitude of the glycemic response (12) .
We tested the hypothesis that muscarinic cholinergic agonism inhibits hepatic glucose production through direct actions, indirect actions or both direct and indirect actions in normal humans. To do so, we measured responses to the muscarinic agonist bethanechol (and the muscarinic antagonist atropine) under conditions in which both direct and indirect actions were expected to be operative, and the responses to bethanechol under conditions in which potential indirect actions were controlled. The latter was accomplished with the islet clamp technique (12) (13) (14) , somatostatin infusion with insulin, glucagon and growth hormone replacement, which holds the levels of islet hormones including glucagon and insulin constant before and after an intervention. This approach permitted demonstration of direct muscarinic cholinergic inhibition of hepatic glucose production in humans.
Methods
Subjects. Nine healthy adults (six men and three women) gave their written consent to participate in these studies which were approved by the Washington University Human Studies Committee and conducted on the Washington University General Clinical Research Center. Six subjects participated in each of the two protocols. Thus, three subjects participated in both protocols. The participants' ages ranged from 20 to 25 yr; all were within 20% of their ideal body weight (Metropolitan Life Insurance Co. Tables, 1983) .
Protocols. All studies were performed after an overnight fast of at least 12 h. On the day of study two intravenous lines, one for infusions and one for sampling, were inserted by 0800 hours. The time of first drug administration was designated 0 min. At -120 min a priming infused intravenously throughout thereafter. Blood samples were obtained at 10-min intervals from -30 through 240 min (first protocol) or 120 min (second protocol), distributed to the appropriate tubes, kept on ice and centrifuged promptly. The supernatants were then frozen for subsequent analysis. Heart rate and blood pressure were recorded (Dinamap Vital Signs Monitor, model 1846; Critikon Inc., Tampa, FL) at 1 0-min intervals; the electrocardiogram was monitored continuously.
In the first protocol 5.0 mg of bethanechol hydrochloride (Merck Sharp and Dohme, West Point, PA), a muscarinic agonist, was administered subcutaneously at 0 min and 1.0 mg of atropine, a muscarinic antagonist, was administered intravenously over 5 min starting at 120 min.
In the second protocol two studies, one with bethanechol administration (clamp plus bethanechol) and one with saline placebo administration (clamp control), were performed during islet clamps in each subject. The islet clamps involved intravenous infusion of somatostatin (Peninsula Laboratories, Belmont, CA), 250 ,gg/h, glucagon (Eli Lilly and Co., Indianapolis, IN), 1.0 ng kg-' min-', and methionyl growth hormone (Genentech Corp., San Francisco, CA), 4.0 ng kg-' min-', in a single solution prepared in 1% human serum albumin in saline. Regular insulin (Novolin; Squibb-Novo, Basgvaerd, Denmark), also prepared in 1% human serum albumin, was infused initially at a variable rate with a syringe infusion pump (Harvard Apparatus Inc., Natick, MA). The insulin infusion rate was adjusted by the investigator at 10-min intervals to achieve steady state plasma glucose concentrations of -90 mg/dl. Thus, the islet clamp technique used here differed from that used previously (12) (13) (14) in that growth hormone was also replaced and initial insulin adjustments were made manually by the investigator rather than with a Biostator. When stable glucose levels were achieved, generally after 3-6 h, the insulin dose was fixed. If glucose levels were stable over the next hour, sampling (-30 min) was then begun and continued through 120 min. Bethanechol or placebo was administered at 0 min. The sequence ofthe clamp control and clamp plus bethanechol studies was varied.
Analytical methods. Plasma glucose was measured with a glucose oxidase method using a glucose analyzer (Beckman Instruments Inc., Fullerton, CA). Plasma insulin and C-peptide (15), glucagon (16) , cortisol (17), growth hormone (18) and pancreatic polypeptide (19) were measured with radioimmunoassays, epinephrine and norepinephrine with a single isotope derivative (radioenzymatic) method (26) . Glucagon was measured on unextracted plasma using an antiserum (G15) provided by Dr. Jonathan Jaspan (University of Chicago). Serum free fatty acids were measured with a colorimetric method (21) . Microfluorimetric methods were used to measure blood fl-hydroxybutyrate (22) , lactate (23) , and alanine (24) . Plasma for glucose radioactivity was precipitated with polyethylene glycol and the supernatant decanted, dried, and reconstituted in distilled water before scintillation counting; glucose production and utilization rates were calculated as described previously (25) .
Statistical methods. Data are presented as the mean plus or minus the standard error. For hormone and metabolic intermediate concentrations comparisons ofinterest were tested for significance with a t test for paired data. For the clamp studies the rates of decline in plasma glucose (initial slopes) were determined using a linear fit of each individual's data from 0 through 60 min; slopes from the clamp control and clamp plus bethanechol studies were also compared with a t test. Areas under the curve for rates of glucose production and utilization were derived from normalized data (i.e., after adjustments for differences at 0 min) for each individual in each study by applying sequential trapezoidal summation between observation points. Those from the clamp control and clamp plus bethanechol studies were then compared with a Wilcoxon signed rank test.
Results
Protocol 1: Bethanechol and atropine administration Plasma glucose concentrations and rates ofglucose production and utilization were unchanged following bethanechol admin-istration and following atropine administration (Fig. 1 ). Plasma pancreatic polypeptide increased from 65±5 pg/ml to a peak of 109±1 (P < 0.01) 40 min after bethanechol injection; it was unchanged following atropine administration (Fig. 1 ). Neither plasma insulin nor C-peptide levels were altered by bethanechol or atropine administration, but plasma glucagon increased from 75±7 pg/ml to a peak of 103±10 pg/ml (P < 0.02) 60 min after bethanechol injection (Fig. 1 ). Apparent increments in plasma norepinephrine (236±36 to 399±121 pg/ml) after bethanechol injection and in plasma epinephrine (28±8 to 93±32 pg/ml) after atropine administration (Fig. 2) were not significant statistically, nor was an apparent increase in plasma cortisol (from 6.2±1.3 to 15.1±5.0 ,gg/dl) after atropine (Fig. 2 ). There were no systematic changes in plasma growth hormone (Fig. 2) . Heart rate increased from 60±4 bpm to a peak of 96±5 bpm (P < 0.01) 20 min after atropine administration (Fig. 2 ).
Apparent increments in serum free fatty acid and blood f,-hydroxybutyrate concentrations after bethanechol injection, and in free fatty acid concentrations following atropine administration, were not significant statistically (Fig. 3 ). Blood lactate and alanine levels tended to decrease over time but were not altered significantly by bethanechol or atropine administration ( Fig. 3 ).
Symptoms that followed bethanechol administration included lacrimation sweating, urinary urgency, and abdominal discomfort. Xerostomia followed atropine administration. Protocol 2: Islet clamps with and without bethanechol Mean plasma glucose concentrations and rates of glucose production and utilization did not change during the clamp control placebo study. In contrast, mean plasma glucose decreased from 101±8 to 8;±6 mg/dl at 60 min and 75±7 mg/dl at 120 min (both P < 0.05) after bethanechol injection in the clamp plus bethanechol study (Fig. 4 ). Both the initial (first 60 min) rate of decline (slope) of the individual plasma glucose concentrations and the area under the glucose production rate curves differed significantly (P < 0.05) between the clamp control and clamp plus bethanechol studies (Fig. 4) . The corresponding slopes and areas under the curves for glucose utilization did not differ significantly between the clamp control and clamp plus bethanechol studies. During the clamp control and clamp plus bethanechol studies plasma concentrations of C-peptide were suppressed and those of pancreatic polypeptide, insulin, and glucagon ( Fig. 5 ) and of cortisol and growth hormone (Fig. 6 ) were unchanged. Apparent late increments in plasma epinephrine (46±17 to 155±47 pg/ml) and early increments in plasma norepinephrine (170±9 to 297±48 pg/ml) following bethanechol injection (Fig. 6 ) were not significant statistically. Serum free fatty acid and blood f3-hydroxybutyrate, lactate, and alanine concentrations did not change after bethanechol injection during the clamp study ( Fig. 7) . by muscarinic cholinergic receptors (26) . To explore the potential role of the parasympathetic nervous system in human glucoregulatory physiology, we measured the responses to subcutaneous injection ofthe muscarinic agonist bethanechol and CLAMP CONTROL to intravenous injection of the musc in normal humans. The adequacy ( denced by typical symptoms and a pancreatic polypeptide concentratic administration, and by symptoms heart rates following atropine admix There was no demonstrable effei gic antagonism with atropine on gl. fasted subjects. Thus, withdrawal does not appear to be an important humans. The same can be said of CLAMP + BET lJ), There was also no net effect of generalized muscarinic . , agonism with bethanechol on plasma glucose concentrations 0 , z or glucose kinetics. However, it was conceivable that a direct 0 60 120 action of muscarinic activation to inhibit hepatic glucose prosoo duction was offset by an indirect action of muscarinic activation, specifically the demonstrated stimulation of glucagon se-300 cretion which would be expected to stimulate hepatic glucose o06 production. To test this possibility we used the islet clamp 0 60 120 technique (12) (13) (14) to hold glucagon (as well as insulin, pancre- 16 atic polypeptide and growth hormone) levels constant before and after bethanechol injection. When an increase in glucagon isecretion was prevented with this technique, muscarinic agon-0 ism resulted in a sharp initial decrease in hepatic glucose pro-0 60 120 duction and a consequent 25% fall in the plasma glucose con-4 centration, changes that did not occur during control studies with the clamp and placebo injection. Thus, direct muscarinic 2-t _cholinergic inhibition of hepatic glucose production occurs in o humans. This finding is consistent with the data of Gardeman 0 60 120 and Jungermann (7) . They found that glucagon-stimulated (min) glucose release from perfused rat livers was reduced by vagal nerve stimulation (in the presence of adrenergic antagonists) ne, norepinephrine, cortisol and that this effect was prevented by atropine. Therefore, parring islet clamp studies with ticularly if regional neuronal firing (to the liver and to the id during islet clamp studies pancreatic islets) occurs, the present data suggest that the parabethanechol) in normal sympathetic nervous system may play an important physiologic role in human glucoregulation. Even if parasympathetic firing were more generalized, it is conceivable that it might alter net hepatic glucose production. We studied the metabolic ,annic antagonist atropine o response to a single dose of bethanechol. The Clearly, the present data do not establish a physiologic role glucoregulatory process in for the parasympathetic nervous system in human glucoregusympathochrtorn proces in-lation, although they raise that possibility. Further studies will be required to determine whether it does, or does not. We believe that such studies are warranted, since parasympathetic activity changes during dynamic metabolic events such as hy-HANECHOL poglycemia (29) and even ingestion of a meal (6, 30, 31) . Finally, we anticipated that muscarinic agonism would result in increased secretion of insulin (6, (31) (32) (33) , an indirect ( mln ) action that would, if anything, have augmented a decrement in acid and blood ,B-hydroxybuhepatic glucose production. However, the plasma concentrais during islet clamp studies tions of insulin and C-peptide were not altered by bethanechol F bethanechol) in normal injection, and hepatic glucose production did not fall, in the initial protocol in which glucagon secretion increased. This supports the conclusion that changes in the secretion of glucagon, rather than insulin, offset direct actions of muscarinic agonism on hepatic glucose production. In summary, the data demonstrate that direct muscarinic cholinergic inhibition of hepatic glucose production occurs in humans. During generalized muscarinic activation this is counteracted by an indirect glucoregulatory action, stimulation ofglucagon secretion. Thus, particularly ifregional neuronal firing (to the liver and to the pancreatic islets) occurs, the parasympathetic nervous system may play an important role in human glucoregulatory physiology.
